
    
      To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic
      peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by
      following clinical outcomes and quality of life measures; and evaluate graft versus host
      disease incidence and severity with regimen.
    
  